61. 自己免疫性溶血性貧血 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158

薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
ALXN1830   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001211-90-IT   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
   Alexion Pharmaceuticals
      2022   Phase 2   NCT04956276   United States;
      2021   Phase 2   NCT04256148   United States;
      2018   Phase 1/Phase 2   NCT03075878   Jordan;United States;
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2021-001211-90-ES   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004055-37-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
ANX005   
   Annexon, Inc
      2020   Phase 2   EUCTR2020-003675-18-IT   Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
   Annexon, Inc.
      2021   Phase 2   EUCTR2020-005854-90-AT   Austria;
      2021   Phase 2   EUCTR2020-003675-18-DE   Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-003675-18-BG   Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United States;
      2021   Phase 2   EUCTR2020-003675-18-AT   Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
APL-2   
   APELLIS PHARMACEUTCIALS, INC.
      2018   Phase 2   EUCTR2017-003363-35-IT   Italy;United States;
   Apellis Pharmaceuticals, Inc.
      2017   Phase 2   NCT03226678   United States;
Acalabrutinib   
   City of Hope Medical Center
      2021   Phase 2   NCT04657094   United States;
BENDAMUSTINE HYDROCHLORIDE   
   Department of Medicine, Haugesund Hospital
      2013   Phase 2   EUCTR2011-004835-30-FI   Denmark;Finland;Norway;
      2013   Phase 2   EUCTR2011-004835-30-DK   Denmark;Finland;Norway;
      2012   Phase 2   EUCTR2011-004835-30-NO   Denmark;Finland;Norway;
BEXSERO – Sospensione iniettabile – Siringa preriempita   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
BIV009   
   Bioverativ, a Sanofi company
      2015   Phase 1   NCT02502903   Austria;
BIVV009   
   BIOVERATIV THERAPEUTICS INC
      2018   Phase 3   EUCTR2017-003539-12-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-IT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
   Bioverativ USA Inc.
      2018   Phase 3   EUCTR2017-003539-12-NL   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003539-12-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003539-12-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-003539-12-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-003538-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
   Bioverativ USA, Inc.
      2018   Phase 3   EUCTR2017-003539-12-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003539-12-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
   Bioverativ a Sanofi Company Inc.
      2018   Phase 3   EUCTR2017-003538-10-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-003538-10-NO   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
BIVV020   
   Bioverativ, a Sanofi company
      2021   Phase 1   NCT04802057   Germany;Italy;Netherlands;Norway;United Kingdom;
      2020   Phase 1   NCT04269551   Canada;Germany;Italy;Netherlands;Norway;Spain;United Kingdom;United States;
Bendamustine, Rituximab   
   Helse Fonna
      2013   Phase 2   NCT02689986   Denmark;Finland;Norway;
Biological assessment   
   Centre Hospitalier Universitaire Dijon
      2022   Phase 2   NCT05089227   France;
Blood sample   
   Centre Hospitalier Universitaire Dijon
      2016   -   NCT02828670   France;
   University Hospital, Bordeaux
      2019   -   NCT04005638   France;
Blood samples   
   Centre Hospitalier Universitaire Dijon
      2013   -   NCT02158195   France;
Bortezomib   
   Gruppo Italiano Malattie EMatologiche dell'Adulto
      2012   Phase 2   NCT01696474   Italy;
CD19/BCMA CAR T-cells   
   Zhejiang University
      2021   Early Phase 1   NCT05263817   China;
CINRYZE® (C1 esterase inhibitor [human])   
   Academic Medical Center
      2013   Phase 2   EUCTR2012-003710-13-NL   Netherlands;
Ciclosporin   
   Tianjin Medical University General Hospital
      2019   Phase 0   ChiCTR1900023476   China;
Combination of a single dose anti-CD20 antibody and bortezomib   
   Peking Union Medical College Hospital
      2019   Phase 2   NCT04083014   China;
Cyclosporine   
   Assiut University
      2021   Phase 3   NCT05057468   Egypt;
Eculizumab   
   University Hospital, Essen
      2011   Phase 2   NCT01303952   Germany;
Fludarabine   
   University of Bergen
      2005   Phase 2   NCT00373594   Norway;Russian Federation;
Fostamatinib 150 mg bid   
   Rigel Pharmaceuticals
      2016   Phase 2   NCT02612558   Canada;United States;
Fostamatinib Disodium   
   RIGEL PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004774-97-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Fostamatinib disodium   
   Rigel Pharmaceuticals
      2019   Phase 3   NCT04138927   Australia;Austria;Belarus;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT03764618   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
INCB050465   
   INCYTE CORPORATION
      2018   Phase 2   EUCTR2017-003652-22-IT   Austria;France;Italy;United States;
   Ueda Eiji
      2021   Phase 3   JPRN-jRCT2051210140   Japan;U.S.A;
INCB050465 HYDROCHLORIDE   
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
   Incyte Coorporation
      2018   Phase 2   EUCTR2017-003652-22-AT   Austria;France;Italy;United States;
   Incyte Corporation
      2022   Phase 3   EUCTR2021-002844-66-NL   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-002844-66-ES   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Ibrutinib   
   Eugene Nikitin
      2017   Phase 2   NCT03827603   Russian Federation;
   Institute of Hematology & Blood Diseases Hospital
      2020   Phase 2   NCT04398459   China;
Interleukine-2   
   University Hospital, Bordeaux
      2017   Phase 1/Phase 2   NCT02389231   France;
Iptacopan   
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2021-002039-40-ES   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 2   EUCTR2021-002039-40-DE   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharmaceuticals
      2021   Phase 2   NCT05086744   Germany;Spain;United Kingdom;
Isatuximab   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
   Sanofi-Aventis Recherche & Developpement
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Isatuximab SAR650984   
   Sanofi
      2021   Phase 1/Phase 2   NCT04661033   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
KZR-616   
   Kezar Life Sciences, Inc.
      2020   Phase 2   NCT04039477   Australia;Italy;Poland;Russian Federation;United States;
Kappa (light chain)   
   Annexon, Inc
      2020   Phase 2   EUCTR2020-003675-18-IT   Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
LEVOCETIRIZINA DICLORIDRATO   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Levact   
   Department of Medicine, Haugesund Hospital
      2013   Phase 2   EUCTR2011-004835-30-FI   Denmark;Finland;Norway;
      2013   Phase 2   EUCTR2011-004835-30-DK   Denmark;Finland;Norway;
      2012   Phase 2   EUCTR2011-004835-30-NO   Denmark;Finland;Norway;
Levamisole   
   Institute of Hematology & Blood Diseases Hospital
      2012   Phase 2   NCT01579110   China;
Levocitirizina   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
M281   
   Janssen Research & Development, LLC
      2019   Phase 2/Phase 3   NCT04119050   Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
   Janssen-Cilag International NV
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-NL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-DE   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-PL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-HU   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-GR   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-CZ   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
   MOMENTA PHARMACEUTICALS, Inc
      2019   Phase 3   EUCTR2019-000720-17-IT   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
   Momenta Pharmaceuticals, Inc.
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-FR   Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-ES   Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
MENVEO – Polvere e soluzione per soluzione iniettabile   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
MabThera   
   Department of Medicine, Haugesund Hospital
      2013   Phase 2   EUCTR2011-004835-30-FI   Denmark;Finland;Norway;
      2013   Phase 2   EUCTR2011-004835-30-DK   Denmark;Finland;Norway;
      2012   Phase 2   EUCTR2011-004835-30-NO   Denmark;Finland;Norway;
Mabthera or biosimilar Rituximab   
   Medical University of Vienna, Department of Internal medicine I
      2016   Phase 2   EUCTR2016-002478-11-AT   Austria;
Nimenrix   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
Ninlaro   
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 2   NCT03965624   France;
Nipocalimab   
   Janssen Research & Development, LLC
      2022   -   NCT05221619   -
   Janssen-Cilag International NV
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-NL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-DE   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-PL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-HU   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-GR   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-CZ   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Orelabrutinib   
   Tianjin Medical University General Hospital
      2021   Phase 4   ChiCTR2100045594   China;
PENTAMIDINA ISETIONATO   
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
PRN1008   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001671-16-IT   China;Denmark;Italy;Spain;United Kingdom;United States;
   Sanofi aventis recherche et developpement
      2021   Phase 2   EUCTR2021-001671-16-ES   China;Denmark;Italy;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-001671-16-DK   China;Denmark;Italy;Spain;United Kingdom;United States;
Parsaclisib   
   Incyte Corporation
      2018   Phase 2   NCT03538041   Austria;France;Italy;United States;
   Ueda Eiji
      2021   Phase 3   JPRN-jRCT2051210140   Japan;U.S.A;
Parsaclisib (1 mg)   
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
   Incyte Corporation
      2022   Phase 3   EUCTR2021-002844-66-NL   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-002844-66-ES   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Parsaclisib (2.5 mg)   
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
   Incyte Corporation
      2022   Phase 3   EUCTR2021-002844-66-NL   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-002844-66-ES   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Parsaclisinib   
   Incyte Corporation
      2022   Phase 3   NCT05073458   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Pentamidine   
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Prednisolone + mabthera   
   Copenhagen University Hospital at Herlev
      2005   Phase 3   NCT01134432   Denmark;
Prednisone   
   Institute of Hematology & Blood Diseases Hospital
      2012   Phase 2   NCT01579110   China;
Prednisone, low dose rituximab   
   Fondazione Ospedale
      2009   Phase 2   NCT01345708   Italy;
R788, fostamatinib disodium hexahydrate (in USPI/FPI)   
   RIGEL PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001882-34-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Rigel Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001882-34-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-FR   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-DK   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004774-97-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-DK   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-BG   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-BE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
R935788   
   RIGEL PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001882-34-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   Rigel Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001882-34-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-FR   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-DK   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001882-34-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004774-97-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-DK   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-BG   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-BE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004774-97-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
RVT-1401   
   Immunovant Sciences GmbH
      2020   Phase 2   EUCTR2019-003924-19-PL   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003924-19-HU   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003924-19-GB   Israel;Korea, Republic of;Romania;Spain;Thailand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003924-19-ES   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Romania;Spain;Thailand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003924-19-BG   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
RVT-1401 340 mg/weekly   
   Immunovant Sciences GmbH
      2020   Phase 2   NCT04253236   Israel;Korea, Republic of;Spain;Thailand;United Kingdom;United States;
RVT-1401 680 mg/weekly   
   Immunovant Sciences GmbH
      2020   Phase 2   NCT04253236   Israel;Korea, Republic of;Spain;Thailand;United Kingdom;United States;
Rapamycin   
   Tianjin Medical University General Hospital
      2019   Phase 0   ChiCTR1900023476   China;
Raptiva 100 mg/ml powder and solvent for solution for injection   
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal;
Recombinant humanized IgG4 monoclonal antibody   
   Annexon, Inc.
      2021   Phase 2   EUCTR2020-005854-90-AT   Austria;
Recombinant humanized monoclonal antibody: IgG4 (heavy chain)   
   Annexon, Inc
      2020   Phase 2   EUCTR2020-003675-18-IT   Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
Rilzabrutinib   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001671-16-IT   China;Denmark;Italy;Spain;United Kingdom;United States;
   Sanofi
      2021   Phase 2   NCT05002777   China;Denmark;Italy;Spain;United Kingdom;United States;
   Sanofi aventis recherche et developpement
      2021   Phase 2   EUCTR2021-001671-16-ES   China;Denmark;Italy;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-001671-16-DK   China;Denmark;Italy;Spain;United Kingdom;United States;
Rituximab   
   Assiut University
      2021   Phase 3   NCT05057481   Egypt;
      2021   Phase 3   NCT05057468   Egypt;
   OSPEDALE MAGGIORE DI MILANO (IRCCS)
      2008   -   EUCTR2008-006713-25-IT   Italy;
   University of Bergen
      2005   Phase 2   NCT00373594   Norway;Russian Federation;
Rituximab (MABTHERA® or RITUXAN®).   
   University Hospital, Toulouse
      2009   -   NCT00960713   France;
Rituximab (Mabthera®)   
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 3   NCT01181154   France;
SAR444671   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001671-16-IT   China;Denmark;Italy;Spain;United Kingdom;United States;
   Sanofi aventis recherche et developpement
      2021   Phase 2   EUCTR2021-001671-16-ES   China;Denmark;Italy;Spain;United Kingdom;United States;
      2021   Phase 2   EUCTR2021-001671-16-DK   China;Denmark;Italy;Spain;United Kingdom;United States;
SAR650984   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
   Sanofi-Aventis Recherche & Developpement
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
SYNT001   
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2021-001211-90-ES   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004055-37-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Sirolimus   
   Children's Hospital of Philadelphia
      2006   Phase 1/Phase 2   NCT00392951   United States;
Soliris (R)   
   Universitätsklinikum Essen
      2010   -   EUCTR2009-016966-97-DE   Germany;
Spleen sample   
   Centre Hospitalier Universitaire Dijon
      2016   -   NCT02828670   France;
Sutimlimab   
   Bioverativ, a Sanofi company
      2018   Phase 3   NCT03347396   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States;
   Sanofi
      2021   Phase 3   NCT05132127   Japan;
   Tanaka Tomoyuki
      2021   Phase 3   JPRN-jRCT2031210392   Japan;
Sutimlimab (BIVV009)   
   Bioverativ, a Sanofi company
      2018   Phase 3   NCT03347422   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States;
TNT009   
   BIOVERATIV THERAPEUTICS INC
      2018   Phase 3   EUCTR2017-003539-12-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-IT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
   Bioverativ USA Inc.
      2018   Phase 3   EUCTR2017-003539-12-NL   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003539-12-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003538-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-003539-12-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-003538-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
   Bioverativ USA, Inc.
      2018   Phase 3   EUCTR2017-003539-12-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003539-12-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
   Bioverativ a Sanofi Company Inc.
      2018   Phase 3   EUCTR2017-003538-10-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-003538-10-NO   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
TRIMETOPRIM + SULFAMETOSSAZOLO *   
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Tacrolimus   
   Peking Union Medical College Hospital
      2019   Phase 4   NCT03918265   China;
Treatment intervention   
   Centre Hospitalier Universitaire Dijon
      2022   Phase 2   NCT05089227   France;
Treatment standard   
   Centre Hospitalier Universitaire Dijon
      2022   Phase 2   NCT05089227   France;
Trimethoprim-sulfamethoxazole   
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Urine sample   
   University Hospital, Bordeaux
      2019   -   NCT04005638   France;
VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)   
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VELCADE*EV 1FL 3,5MG 1MG/ML   
   G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
      2012   Phase 2   EUCTR2011-006329-42-IT   Italy;
 LNP023 HYDROCHLORIDE SALT   
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2021-002039-40-ES   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 2   EUCTR2021-002039-40-DE   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;